Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 8/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.43 |
| ▸ | F13A1 | P00488 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20659611 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1892347 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1889345 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1898999 | 1.00 | TBXAS1 (0.50) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL1650867 | 0.93 | TBXAS1 (0.41) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL29267785 | 0.86 | TBXAS1 (0.43) | TBXAS1LMNATSHRNFKB1PMP22 | |
| SCHEMBL6532553 | 0.86 | TBXAS1 (0.36) | TBXAS1CYP1A2CYP2C19 | |
| SCHEMBL2704416 | 0.85 | CHRM1 (0.39) | TBXAS1LMNAFFAR1ALDH1A1 | |
| SCHEMBL12287350 | 0.84 | PAOX (0.38) | TBXAS1MAPTALDH1A1 | |
| SCHEMBL12287701 | 0.84 | PAOX (0.38) | TBXAS1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 116 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1765408-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-12-09 | — | — | EP | claimed |
| US-9061067-B2 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2015-06-23 | — | — | US | claimed |
| EP-2289560-B1 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK AS (DK) | 2015-04-22 | — | — | EP | claimed |
| US-20090111730-A1 | Polypeptide protracting tags | NOVO NORDISK A/S (DK) | 2009-04-30 | — | — | US | claimed |
| CN-101005857-A | Polypeptide protracting tags | NOVO NORDISK AS (DK) | 2007-07-25 | — | — | CN | claimed |
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | NOVO NORDISK AS (DK) | 2023-11-16 | — | — | US | disclosed |
| CN-108473550-B | EGF (A) analogues with fatty acid substituents | 诺和诺德股份有限公司 | 2022-11-22 | — | — | CN | disclosed |
| EP-3402811-B1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | NOVO NORDISK AS (DK) | 2022-03-30 | — | — | EP | disclosed |
| US-20210094999-A1 | Novel Acylated Insulin Analogues and Uses Thereof | NOVO NORDISK AS (DK) | 2021-04-01 | — | — | US | disclosed |
| US-10919949-B2 | Acylated insulin analogues and uses thereof | NOVO NORDISK A/S (DK) | 2021-02-16 | — | — | US | disclosed |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | CHEN JIANHE (CN) | 2020-12-31 | — | — | US | disclosed |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | NOVO NORDISK A/S (DK) | 2020-11-03 | — | — | US | disclosed |
| WO-2008087186-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| WO-2008087186-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2008-07-24 | — | — | WO | disclosed |
| EP-1907010-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | Novo Nordisk A/S (DK) | 2008-04-09 | — | — | EP | disclosed |
| CN-101005857-A | Polypeptide protracting tags | NOVO NORDISK AS (DK) | 2007-07-25 | — | — | CN | disclosed |
| EP-1765408-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2007-03-28 | — | — | EP | disclosed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | disclosed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | disclosed |
| WO-2006005667-A2 | POLYPEPTIDE PROTRACTING TAGS COMPRISING A TETRAZOLE MOIETY | NOVO NORDISK A/S (DK) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364248-A1 | MIC-1 COMPOUNDS AND USES THEREOF | IMMT, MICA, TAP1 | TBXAS1 3667/4885LMNA 3561/4885TSHR 4684/4885 |
| US-10919949-B2 | Acylated insulin analogues and uses thereof | IAPP, GPR119, INSR | TBXAS1 1622/4885LMNA 2070/4885TSHR 681/4885 |
| US-10822385-B2 | EGF(A) analogues with fatty acid substituents | EGFR, LDLR, FFAR2 | TBXAS1 944/4885LMNA 2338/4885TSHR 265/4885 |
| US-20200407409-A1 | EGF(A) ANALOGUES WITH FATTY ACID SUBSTITUENTS | EGFR, LDLR, FFAR2 | TBXAS1 944/4885LMNA 2338/4885TSHR 265/4885 |
| US-20210094999-A1 | Novel Acylated Insulin Analogues and Uses Thereof | IAPP, GPR119, INSR | TBXAS1 1187/4885LMNA 2378/4885TSHR 753/4885 |
| US-20090111730-A1 | Polypeptide protracting tags | LNPEP, FGB, ENPEP | TBXAS1 2192/4885LMNA 657/4885TSHR 553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.